A randomized trial examined the effects of different progestogens on sleep quality in postmenopausal women with insomnia. One hundred Thai women were assigned to receive estradiol valerate (1 mg) combined with either dydrogesterone (10 mg) or micronized progesterone (100 mg) daily. Over three months, both groups showed significant improvements in
This systematic review assessed the impact of micronized progesterone combined with estrogen on breast cancer risk in postmenopausal women with an intact uterus. The study found that short-term use (up to 5 years) of this combination did not significantly increase the risk of breast cancer, but limited evidence suggested that
This study examined the sedative and hypnotic effects of orally administered micronized progesterone in eight postmenopausal women. A 400 mg dose induced a hypnotic state lasting approximately two hours in one participant, while serum levels of progesterone and its metabolites peaked between 2 to 6 hours post-administration. The study identified
This article reviews the use of oral micronized progesterone as a preferred alternative to synthetic progestins in hormone replacement therapy for postmenopausal women. It highlights that while unopposed estrogen therapy increases the risk of endometrial hyperplasia and cancer, the addition of progesterone effectively mitigates this risk. Micronized progesterone, with comparable
A 2021 systematic review and meta-analysis published in the Journal of Clinical Endocrinology & Metabolism (PMID: 33245776) assessed the impact of micronized progesterone on sleep outcomes, particularly in postmenopausal women. The study analyzed nine randomized controlled trials with a total of 388 participants. Results indicated that micronized progesterone improved sleep
This observational study from the E3N-EPIC cohort investigated the relationship between various hormone replacement therapy (HRT) regimens and breast cancer risk. The study found that combining estrogens with synthetic progestins increased breast cancer risk, even for short durations, while transdermal estrogens with synthetic progestins also showed an elevated risk. However,
The article “Diagnostic and therapeutic use of oral micronized progesterone in endocrinology” (Rev Endocr Metab Disord, 2024, PMID: 38652231) reviews the role of micronized progesterone (MP) in diagnosing and treating various endocrine disorders. MP, with its enhanced bioavailability due to micronization, is used diagnostically to assess primary or secondary amenorrhea
This study examined the effects of oral estradiol combined with either micronized progesterone or medroxyprogesterone acetate on breast cancer risk markers in postmenopausal monkeys. Results showed that estradiol with medroxyprogesterone acetate significantly increased breast epithelial proliferation and expression of proliferation markers (Ki67, cyclin B1) compared to placebo (P < 0.01),
